Cargando…
Leveraging epigenetics to enhance the efficacy of immunotherapy
BACKGROUND: Epigenetic mechanisms regulate chromatin accessibility patterns that govern interaction of transcription machinery with genes and their cis-regulatory elements. Mutations that affect epigenetic mechanisms are common in cancer. Because epigenetic modifications are reversible many anticanc...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130138/ https://www.ncbi.nlm.nih.gov/pubmed/34001289 http://dx.doi.org/10.1186/s13148-021-01100-x |
_version_ | 1783694455789846528 |
---|---|
author | Licht, Jonathan D. Bennett, Richard L. |
author_facet | Licht, Jonathan D. Bennett, Richard L. |
author_sort | Licht, Jonathan D. |
collection | PubMed |
description | BACKGROUND: Epigenetic mechanisms regulate chromatin accessibility patterns that govern interaction of transcription machinery with genes and their cis-regulatory elements. Mutations that affect epigenetic mechanisms are common in cancer. Because epigenetic modifications are reversible many anticancer strategies targeting these mechanisms are currently under development and in clinical trials. MAIN BODY: Here we review evidence suggesting that epigenetic therapeutics can deactivate immunosuppressive gene expression or reprogram tumor cells to activate antigen presentation mechanisms. In addition, the dysregulation of epigenetic mechanisms commonly observed in cancer may alter the immunogenicity of tumor cells and effectiveness of immunotherapies. CONCLUSIONS: Therapeutics targeting epigenetic mechanisms may be helpful to counter immune evasion and improve the effectiveness of immunotherapies. |
format | Online Article Text |
id | pubmed-8130138 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-81301382021-05-18 Leveraging epigenetics to enhance the efficacy of immunotherapy Licht, Jonathan D. Bennett, Richard L. Clin Epigenetics Review BACKGROUND: Epigenetic mechanisms regulate chromatin accessibility patterns that govern interaction of transcription machinery with genes and their cis-regulatory elements. Mutations that affect epigenetic mechanisms are common in cancer. Because epigenetic modifications are reversible many anticancer strategies targeting these mechanisms are currently under development and in clinical trials. MAIN BODY: Here we review evidence suggesting that epigenetic therapeutics can deactivate immunosuppressive gene expression or reprogram tumor cells to activate antigen presentation mechanisms. In addition, the dysregulation of epigenetic mechanisms commonly observed in cancer may alter the immunogenicity of tumor cells and effectiveness of immunotherapies. CONCLUSIONS: Therapeutics targeting epigenetic mechanisms may be helpful to counter immune evasion and improve the effectiveness of immunotherapies. BioMed Central 2021-05-17 /pmc/articles/PMC8130138/ /pubmed/34001289 http://dx.doi.org/10.1186/s13148-021-01100-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Licht, Jonathan D. Bennett, Richard L. Leveraging epigenetics to enhance the efficacy of immunotherapy |
title | Leveraging epigenetics to enhance the efficacy of immunotherapy |
title_full | Leveraging epigenetics to enhance the efficacy of immunotherapy |
title_fullStr | Leveraging epigenetics to enhance the efficacy of immunotherapy |
title_full_unstemmed | Leveraging epigenetics to enhance the efficacy of immunotherapy |
title_short | Leveraging epigenetics to enhance the efficacy of immunotherapy |
title_sort | leveraging epigenetics to enhance the efficacy of immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130138/ https://www.ncbi.nlm.nih.gov/pubmed/34001289 http://dx.doi.org/10.1186/s13148-021-01100-x |
work_keys_str_mv | AT lichtjonathand leveragingepigeneticstoenhancetheefficacyofimmunotherapy AT bennettrichardl leveragingepigeneticstoenhancetheefficacyofimmunotherapy |